Did Unrecognized Cardiac Amyloidosis Hinder Recent HFpEF Trials? Did Unrecognized Cardiac Amyloidosis Hinder Recent HFpEF Trials?

Routinely screening for cardiac amyloid and excluding those patients might increase the chances of finding efficacious treatments for heart failure with preserved ejection fraction, researchers suggest.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news